Liquidia (NASDAQ:LQDA) Shares Gap Up – What’s Next?

Liquidia Corporation (NASDAQ:LQDA)’s share price gapped up prior to trading on Monday. The stock had previously closed at $27.38, but opened at $29.27. Liquidia shares last traded at $29.0220, with a volume of 955,427 shares.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Analysts Set New Price Targets

LQDA has been the subject of several research reports. Raymond James Financial reaffirmed an “outperform” rating on shares of Liquidia in a report on Thursday, October 8th. Royal Bank Of Canada set a $130.00 price objective on shares of Liquidia in a research note on Friday, July 24th. Bank of America increased their price objective on shares of Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Citigroup reissued a “neutral” rating on shares of Liquidia in a report on Thursday, October 1st. Finally, Wells Fargo & Company restated an “equal weight” rating and issued a $30.00 target price (down from $108.00) on shares of Liquidia in a research note on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $83.69.

Liquidia Stock Performance

The stock has a market capitalization of $2.40 billion, a P/E ratio of 19.57 and a beta of 0.61. The stock has a 50 day moving average of $63.40 and a 200 day moving average of $61.76. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter in the previous year, the business posted ($0.49) earnings per share. The business’s quarterly revenue was up 1842.1% compared to the same quarter last year. Equities analysts predict that Liquidia Corporation will post 2.05 EPS for the current year.

Insiders Place Their Bets

In other Liquidia news, insider Sarah Krepp sold 5,245 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $149,377.60. Following the completion of the transaction, the insider directly owned 115,241 shares of the company’s stock, valued at $3,282,063.68. The trade was a 4.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Rajeev Saggar sold 9,218 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $262,528.64. Following the transaction, the insider directly owned 126,368 shares of the company’s stock, valued at $3,598,960.64. The trade was a 6.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 745,194 shares of company stock worth $41,081,702. 25.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Liquidia

Several large investors have recently made changes to their positions in the company. Globeflex Capital L P acquired a new position in shares of Liquidia during the second quarter worth approximately $175,000. Nykredit A S bought a new position in Liquidia in the 2nd quarter worth approximately $177,000. Hurley Capital LLC increased its position in Liquidia by 140.7% in the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock valued at $179,000 after acquiring an additional 3,040 shares during the period. Apollon Wealth Management LLC acquired a new stake in Liquidia in the 1st quarter valued at approximately $247,000. Finally, Archer Investment Corp acquired a new stake in Liquidia in the 1st quarter valued at approximately $259,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).